Trial · NCT02973477
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Changes in Measure of Heart Rate Variability Using Dapagliflozin vs Active Comparator Glimepiride. | First Dapagliflozin Then Glimepiride | value at 12 weeks minus value at 1st baseline | -0.18 | Standard Deviation 1.51 | LF:HF ratio |
| Changes in Measure of Heart Rate Variability Using Dapagliflozin vs Active Comparator Glimepiride. | First Glimepiride Then Dapagliflozin | value at 12 weeks minus value at 1st baseline | -0.34 | Standard Deviation 1.54 | LF:HF ratio |
| Changes in Measure of Heart Rate Variability Using Dapagliflozin vs Active Comparator Glimepiride. | First Dapagliflozin Then Glimepiride | value at 26 weeks minus value at 2nd baseline | 0.26 | Standard Deviation 1.85 | LF:HF ratio |
| Changes in Measure of Heart Rate Variability Using Dapagliflozin vs Active Comparator Glimepiride. | First Glimepiride Then Dapagliflozin | value at 26 weeks minus value at 2nd baseline | 0.26 | Standard Deviation 1.92 | LF:HF ratio |
| Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride. | Participants Who Received Dapagliflozin Intervention | SDNN before treatment | 40.72 | Standard Deviation 16.63 | msec |
| Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride. | Participants Who Received Glimepiride Intervention | SDNN before treatment | 39.75 | Standard Deviation 16.15 | msec |
| Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride. | Participants Who Received Dapagliflozin Intervention | SDNN after treatment | 37.74 | Standard Deviation 16.04 | msec |
| Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride. | Participants Who Received Glimepiride Intervention | SDNN after treatment | 36.46 | Standard Deviation 17.68 | msec |
| Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride. | Participants Who Received Dapagliflozin Intervention | rmsSD before treatment | 26.91 | Standard Deviation 17.81 | msec |
| Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride. | Participants Who Received Glimepiride Intervention | rmsSD before treatment | 25.14 | Standard Deviation 13.06 | msec |
| Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride. | Participants Who Received Dapagliflozin Intervention | rmsSD after treatment | 24.30 | Standard Deviation 16.44 | msec |
| Changes in Measures of Heart Rate Variability (HRV) Using Dapagliflozin vs Active Comparator Glimepiride. | Participants Who Received Glimepiride Intervention | rmsSD after treatment | 24.63 | Standard Deviation 17.38 | msec |
| Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs) | All Participants Who Received Dapagliflozin | E/I ratio before treatment | 1.13 | Standard Deviation 0.07 | ratio |
| Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs) | All Participants Who Received Glimiperide | E/I ratio before treatment | 1.14 | Standard Deviation 0.08 | ratio |
| Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs) | All Participants Who Received Dapagliflozin | EI ratio after treatment | 1.14 | Standard Deviation 0.11 | ratio |
| Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs) | All Participants Who Received Glimiperide | EI ratio after treatment | 1.14 | Standard Deviation 0.13 | ratio |
| Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs) | All Participants Who Received Dapagliflozin | Valsalva ratio before treatment | 1.50 | Standard Deviation 0.36 | ratio |
| Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs) | All Participants Who Received Glimiperide | Valsalva ratio before treatment | 1.44 | Standard Deviation 0.29 | ratio |
| Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs) | All Participants Who Received Dapagliflozin | Valsalva ratio after treatment | 1.60 | Standard Deviation 0.66 | ratio |
| Changes in Measures of Cardiac Autonomic Reflex Testing (CARTs) | All Participants Who Received Glimiperide | Valsalva ratio after treatment | 1.58 | Standard Deviation 0.85 | ratio |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02973477/results